- 11/14/2017IR
Supplement Documents for Financial Results Q3 FY12/17
Supplement Documents for Financial Results Q3 FY12/17
- 11/14/2017IR
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended September 30, 2017
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended September 30, 2017
- 09/27/2017IR
Licence Agreement for anti-DLK-1 antibody development and commercialization
Licence Agreement for anti-DLK-1 antibody development and commercialization
- 08/10/2017IR
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2017
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2017
- 08/10/2017IR
Supplement Documents for Financial Results Q2 FY12/17
Supplement Documents for Financial Results Q2 FY12/17
- 06/26/2017IR
Receipt of a formal notification associated with Option License Agreements of LIV-1205 and LIV-2008b
Receipt of a formal notification associated with Option License Agreements of LIV-1205 and LIV-2008b
- 05/15/2017IR
Supplement Documents for Financial Results Q1 FY12/17
Supplement Documents for Financial Results Q1 FY12/17
- 05/15/2017IR
Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31, 2017
Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31, 2017
- 02/14/2017IR
Supplement Documents for Financial Results FY12/16
Supplement Documents for Financial Results FY12/16
- 02/14/2017IR
Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2016
Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2016
- Top
- News